TheEdgeResearch
Home / Stocks / IVA

Inventiva S.A. (IVA)

NASDAQ Healthcare Biotechnology
$3.14 ▼ -8.99%
Market Cap
$163.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.91
52-Wk Range
2.82-7.29
CEO
Andrew Obenshain
Country
FR
Currency
USD

Inventiva S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Daix, BF, FR. The stock last traded at $3.14, down 8.99% on the session, giving a market capitalisation of $163.2M. On trailing twelve-month figures it carries a trailing P/E of -5.54, a net margin of -505557.1%. Its beta of 0.91 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-5.54
Price / Sales
14321.76
Price / Book
13.61
EV / EBITDA
-16.13
Gross margin
-5232.7%
Operating margin
-306726.5%
Net margin
-505557.1%
Return on equity
—
Debt / equity
1.13
Current ratio
3.81
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
77
IPO date
2020-07-10
Headquarters
Daix, BF, FR
About Inventiva S.A.

Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.

Comparable companies

Inventiva S.A. is most often compared with the following Healthcare names:

AVTXCRBUENTAEPRXGNFTIVVDNAUTOBIORNACTNYA
More research on IVA
IVA technical analysis IVA TheEdge Score Compare against peers
Open full interactive analysis & DCF →